The figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
A narrower follow-up, since the general answer is now clear:
How often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning?
jason_paloalto said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
Coming at jason_paloalto’s question from a different direction. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsClosing the loop on my own question.
Took the whole panel in rather than the one flagged line, and the conversation lasted two minutes instead of generating three more tests.
Dr.NephBHM_UK said:The liver data is among the strongest non-weight findings in the class.
That is correct as far as it goes, and here is where it stops going. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.